Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Go back to Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 197.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $197.74 | 52 Week High | $333.65 | |||
| Open | $197.74 | 52 Week Low | $223.02 | |||
| Day High | $197.74 | P/E | 25.32 | |||
| Day Low | $197.74 | EPS | $7.81 | |||
| Volume | 4 | |||||
